Genetic Variation of G6PD and CYP2D6: Clinical Implications on the Use of Primaquine for Elimination of Plasmodium vivax
Primaquine, an 8-aminoquinoline, is the only medication approved by the World Health Organization to treat the hypnozoite stage of Plasmodium vivax and P. ovale malaria. Relapse, triggered by activation of dormant hypnozoites in the liver, can occur weeks to years after primary infection, and provid...
Saved in:
Main Authors: | Alexandra G. A. Stewart (Author), Peter A. Zimmerman (Author), James S. McCarthy (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Global perspectives on CYP2D6 associations with primaquine metabolism and Plasmodium vivax radical cure
by: Jasmine M. Olvany, et al.
Published: (2022) -
Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria.
by: Walter R J Taylor, et al.
Published: (2021) -
Linked-evidence modelling of qualitative G6PD testing to inform low- and intermediate-dose primaquine treatment for radical cure of Plasmodium vivax.
by: Michelle L Gatton
Published: (2024) -
Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: A cost-effectiveness analysis.
by: Angela Devine, et al.
Published: (2017) -
Pharmacogene Variation in Thai Plasmodium vivax Relapse Patients Treated with a Combination of Primaquine and Chloroquine
by: Chamnanphon M, et al.
Published: (2020)